INCOME TAXES	9 Months Ended
Sep. 30, 2012
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three months and nine months ended September 30, 2012, the effective tax rate (ETR) was 16.3% and 24.0%, respectively, compared with 22.6% and 27.1% for the same periods in 2011. The lower ETR was primarily attributable to changes in management’s assertion that certain current and prior years’ foreign earnings and profits are permanently invested abroad, favorable return-to-provision adjustments arising from the filing of the Company’s 2011 U.S. federal income tax return, and a change in the geographic earnings mix. The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of September 30, 2012 and December 31, 2011 was $63.3 million and $37.9 million, respectively. The increase in the gross reserve for uncertain tax positions is primarily due to a reassessment of the Company’s global tax positions, recorded in Other Liabilities, and is equally offset by an increase in other tax receivables, recorded in Other Assets. Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (BMS), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.2 million as of September 30, 2012. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.

INCOME TAXES

9 Months Ended

Sep. 30, 2012

For the three months and nine months ended September 30, 2012, the effective tax rate (ETR) was 16.3% and 24.0%, respectively, compared with 22.6% and 27.1% for the same periods in 2011. The lower ETR was primarily attributable to changes in management’s assertion that certain current and prior years’ foreign earnings and profits are permanently invested abroad, favorable return-to-provision adjustments arising from the filing of the Company’s 2011 U.S. federal income tax return, and a change in the geographic earnings mix.

The Company’s gross reserve for uncertain tax positions related to foreign and domestic matters, including penalties and interest, as of September 30, 2012 and December 31, 2011 was $63.3 million and $37.9 million, respectively. The increase in the gross reserve for uncertain tax positions is primarily due to a reassessment of the Company’s global tax positions, recorded in Other Liabilities, and is equally offset by an increase in other tax receivables, recorded in Other Assets.

Pursuant to the Amended and Restated Tax Matters Agreement dated December 18, 2009, Bristol-Myers Squibb Company (BMS), the Company’s former parent, maintains responsibility for all uncertain tax positions which may exist in the pre-initial public offering period or which may exist as a result of the initial public offering transaction. The Company has recorded a receivable from BMS for uncertain tax positions, including penalties and interest, of $8.2 million as of September 30, 2012. The Company believes that it has adequately provided for all uncertain tax positions. It is reasonably possible that new issues may be raised by tax authorities and that these issues may require increases in the balance of uncertain tax positions.